Realty Income's management, led by CEO Sumit Roy, leverages private equity expertise to drive long-term growth of 5% to 6% ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

BridgeBio possesses a medium revenue cyclicality rating, and its operating leverage has a low rating. We assess the company's balance sheet as weak due to management's dependence on debt issuance to ...